Table 5 Correlation between MAP-tau expression and clinicopathologic variables in TAX 307S
| Â | MAP-tau expression | Â | |
|---|---|---|---|
Variable | Low (%) (AQUA score < 462) | High (%) (AQUA score > 462) | P* |
Menopausal status | Â | Â | Â |
   Premenopausal | 15 (17.1) | 9 (10.2) | 0.487 |
   Postmenopausal | 45 (51.1) | 19 (21.6) |  |
Tumor size (cm) | Â | Â | Â |
   ≤ 2 | 13 (12.8) | 11 (10.8) | 0.137 |
   2-5 | 40 (39.2) | 16 (15.6) |  |
   ≥ 5 | 15 (14.7) | 7 (6.9) |  |
Nodal status | Â | Â | Â |
   Negative for node metastasis | 23 (24.2) | 10 (10.5) | 0.922 |
   Positive for node metastasis | 41 (43.2) | 21 (22.1) |  |
Tumor grade | Â | Â | 0.140 |
   Well/moderately differentiated | 19 (21.1) | 12 (13.3) |  |
   Poorly/undifferentiated | 45 (50.0) | 14 (15.6) |  |
ER status | Â | Â | Â |
   ER negative | 32 (35.6) | 8 (8.9) | 0.005 |
   ER positive | 26 (28.9) | 24 (26.7) |  |
PR status | Â | Â | Â |
   PR negative | 30 (34.5) | 11 (12.6) | 0.103 |
   PR positive | 26 (29.9) | 20 (22.9) |  |
Prior adjuvant chemotherapy | Â | Â | Â |
   No therapy | 30 (27.8) | 25 (23.2) | 0.002 |
   Yes therapy | 43 (39.8) | 10 (9.3) |  |
Prior adjuvant hormonal therapy | Â | Â | Â |
   No therapy | 47 (43.5) | 24 (22.2) | 0.666 |
   Yes therapy | 26 (24.1) | 11 (10.2) |  |
Prior metastatic hormonal therapy | Â | Â | Â |
   No therapy | 56 (51.9) | 24 (22.2) | 0.371 |
   Yes therapy | 17 (15.7) | 11 (10.2) |  |
Response to therapy | Â | Â | Â |
   Complete response (CR) | 6 (5.9) | 2 (1.9) | 0.518 |
   Partial response (PR) | 30 (29.7) | 18 (17.8) |  |
   Stable disease (SD) | 20 (19.8) | 9 (8.9) |  |
   Progressive disease (PD) | 13 (12.9) | 3 (2.9) |  |
Treatment | Â | Â | Â |
   FAC1 | 39 (36.1) | 15 (13.9) | 0.303 |
   TAC2 | 34 (31.5) | 20 (18.5) |  |